RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events
May 06, 2024 - The money pouring into ADCs is a reminder of just how important oncology is to the pharmaceutical sector, even as obesity steals the limelight. It is the industry’s biggest source of sales, with projected 2028 revenues of $440bn, says data provider IQVIA. Drugs that precisely target cancerous cells look set to play a crucial role in treating the disease, unleashing another wave of oncology growth.
[ While ADCs induce tumor-specific adaptrive immunity, increasing the infiltration of T cells into the tumor microenvironment, ADC's ultimately lose their effectiveness, as a result of T cell resistance and exhaustion, due to the slow-release of the chemotherapy payload and increasing level of side effects, thus precluding optimal sequencing with other immunotherapy agents such as checkpoint inhibitors. Consequently, ONCY's pelareorep is able to step-up when this occurs, to both stimulate the innate and adaptive immune system and to remodel the tumor microenvironment (TME), thus enhancing the CD8+-TiLs complex to increase T-cell expansion, and prepare the landscape for the synergistic addition of immune checkpoint inhibition. ]
https://www.ft.com/content/85ab8fe2-d1ec-47e9-83f9-4802682a1c94